- The disease
- Stroke is a medical emergency caused either by a blocked blood vessel (ischaemic stroke) or by bleeding in the brain (hemorrhagic stroke, also called intracranial hemorrhage). Distinguishing between the two types is critical because the treatments differ and giving the wrong treatment can be harmful. Currently, paramedics cannot differentiate stroke type in the field; patients must reach a hospital with CT (computed tomography) or MRI (magnetic resonance imaging) scanning before a diagnosis can be confirmed. This delay can extend the time before appropriate treatment begins.
- What the asset is trying to do
- The emu First Responder is a portable, wearable electromagnetic brain scanner designed to be used by paramedics in a pre-hospital setting, such as inside an ambulance (per EMVision company disclosures). It uses microwave imaging technology to detect differences in the electromagnetic properties of brain tissue, which can indicate the presence of blood from a hemorrhage. The device differs from existing hospital-based CT and MRI scanners in that it is compact and designed for non-radiologist operators in the field, rather than requiring specialist hospital infrastructure.
- What the trial is measuring, and why it matters
- The trial (NCT06999122) is measuring the diagnostic performance of the emu device in detecting intracranial hemorrhage in patients with suspected stroke (per ClinicalTrials.gov NCT06999122). Diagnostic performance in this context typically involves comparing the device's findings against a reference standard, such as hospital CT imaging, to determine how accurately the device identifies or rules out bleeding. Accurate pre-hospital detection of hemorrhage is considered clinically meaningful because it could allow faster triage and treatment decisions.
- Efficacy benchmarks in this setting
- In the hospital setting, non-contrast CT is the established reference standard for detecting intracranial hemorrhage, with sensitivity reported to be high (specific figures vary by study design and hemorrhage subtype). For context, a meta-analysis by Hallevi et al. and subsequent literature have reported CT sensitivities for acute intracranial hemorrhage generally above 90% in controlled hospital conditions; analysts seeking a precise benchmark should consult published diagnostic accuracy studies and the relevant device regulatory submissions directly. The emu device is in an early-stage diagnostic accuracy study; its figures, when reported, will not be statistically comparable to those from established hospital-based modalities given differences in patient populations, scan timing, operator training, and study design.
- Commercial context
- No portable pre-hospital electromagnetic brain scanner is currently approved for use in stroke triage in Australia or the United States based on publicly available regulatory agency records. The emu First Responder is described by the company as a world-first pre-hospital study, conducted in partnership with Ambulance Victoria and Royal Melbourne Hospital (per EMVision ASX disclosures). EMVision received a $1.17 million instalment from the Industry Growth Programme (IGP) grant (per ASX announcement dated 2026-05-24) and received a $3.8 million R&D tax rebate (per ASX announcement dated 2026-03-15). A separate aeromedical study has been announced, described by the company as de-risking rural and remote use cases (per ASX announcement dated 2026-05-26). The emu First Responder appears to be the company's lead asset based on available public disclosures.